COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in <i>BRAF</i> V600–Mutant Advanced Melanoma

Antoni Ribas, Caroline Robert, Dirk Schadendorf, Georgina V. Long, Hussein Tawbi, Keith Flaherty, Paolo A. Ascierto, Paul Nathan, Piotr Rutkowski, Oleg V. Leonov, Paul Lorigan, Sorilla Prey, Maristella Saponara, Ana Arance, Caroline Gaudy-Marqueste, Daniil Stroyakovskiy, Celeste Lebbe, Michele Maio, Michele Del Vecchio, Pamela Salman Boghikian, Ralf Gutzmer, Roberta Depenni, Marina Miskic, Mark Russo, Reinhard Dummer

Open source

DOI: 10.1200/jco-26-00528
Published: 2026-09-10
Container: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-26-00528,
  title = {COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in
                    <i>BRAF</i>
                    V600–Mutant Advanced Melanoma},
  author = {Antoni Ribas and Caroline Robert and Dirk Schadendorf and Georgina V. Long and Hussein Tawbi and Keith Flaherty and Paolo A. Ascierto and Paul Nathan and Piotr Rutkowski and Oleg V. Leonov and Paul Lorigan and Sorilla Prey and Maristella Saponara and Ana Arance and Caroline Gaudy-Marqueste and Daniil Stroyakovskiy and Celeste Lebbe and Michele Maio and Michele Del Vecchio and Pamela Salman Boghikian and Ralf Gutzmer and Roberta Depenni and Marina Miskic and Mark Russo and Reinhard Dummer},
  year = {2026},
  journal = {Journal of Clinical Oncology},
  doi = {10.1200/jco-26-00528},
  url = {https://doi.org/10.1200/jco-26-00528}
}

RIS

TY  - JOUR
TI  - COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in
                    <i>BRAF</i>
                    V600–Mutant Advanced Melanoma
AU  - Antoni Ribas
AU  - Caroline Robert
AU  - Dirk Schadendorf
AU  - Georgina V. Long
AU  - Hussein Tawbi
AU  - Keith Flaherty
AU  - Paolo A. Ascierto
AU  - Paul Nathan
AU  - Piotr Rutkowski
AU  - Oleg V. Leonov
AU  - Paul Lorigan
AU  - Sorilla Prey
AU  - Maristella Saponara
AU  - Ana Arance
AU  - Caroline Gaudy-Marqueste
AU  - Daniil Stroyakovskiy
AU  - Celeste Lebbe
AU  - Michele Maio
AU  - Michele Del Vecchio
AU  - Pamela Salman Boghikian
AU  - Ralf Gutzmer
AU  - Roberta Depenni
AU  - Marina Miskic
AU  - Mark Russo
AU  - Reinhard Dummer
PY  - 2026
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco-26-00528
UR  - https://doi.org/10.1200/jco-26-00528
ER  -

APA

Ribas, A., Robert, C., Schadendorf, D., Long, G. V., Tawbi, H., Flaherty, K., Ascierto, P. A., Nathan, P., Rutkowski, P., Leonov, O. V., Lorigan, P., Prey, S., Saponara, M., Arance, A., Gaudy-Marqueste, C., Stroyakovskiy, D., Lebbe, C., Maio, M., Vecchio, M. D., Boghikian, P. S., Gutzmer, R., Depenni, R., Miskic, M., Russo, M., & Dummer, R. (2026). COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in <i>BRAF</i> V600–Mutant Advanced Melanoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00528

Source records

crossref · retrieved 2026-09-26T06:43:36.442Z